L. Repetto et al., INTERFERONS IN THE TREATMENT OF ADVANCED BREAST-CANCER, Journal of biological regulators and homeostatic agents, 7(4), 1993, pp. 109-114
In the past two decades interferons have undergone extensive phase I a
nd II evaluations in various types of cancers, including breast cancer
. This article reviews the experience, obtained from preclinical and c
linical studies, about the clinical rationale efficacy and toxicity of
interferons in cancer treatment In particular, we examine the preclin
ical experience in which antineoplastic activity of interferon against
breast cancer has been demonstrated Finally we discuss clinical data
accumulated using interferon-alpha, interferon-beta and lymphoblastoid
interferon alone or in combination in metastatic breast cancer patien
ts. The use of the interferons in the treatment of breast cancer remai
ns investigational and the optimal scheduling undetermined. New method
s of administration may maximize the antitumor effects in order to bet
ter understand the role of interferon in clinical oncology.